Lipoprotein (a) and antisense oligonucleotides
PDF (Español (España))
HTML (Español (España))


Oligonucleotides Antisense

How to Cite

Contreras-Romero, J. A., Castro Gomez, K. G. ., Morales Ortigoza, M. P. ., & Saavedra López, H. F. . (2023). Lipoprotein (a) and antisense oligonucleotides. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 10(3).


Background: Lipoprotein(a) (Lp(a)) was first described by geneticist Kare Berg in 1963, isolated as a new antigen (in human serum), associated with low-density lipoprotein cholesterol. Subsequently, it was reported that its levels are determined genetically and prompted a greater risk of developing atherosclerosis. For the last 20 years, evidence about the structure, genetics, and metabolic roles of Lp(a) has increased, as well as possible therapies to reduce its atherogenicity.

Objective: Provide information about the role of Lp(a) in atherosclerotic disease and evaluate new evidence about current therapies, mainly the role of antisense oligonucleotides.

Methodology: Literature review in the PubMed database, Google Scholar, and gray literature using the MeSH terms: “lipoprotein(a),” “atherosclerosis,” “physiopathology,” “therapeutics,” “drug therapy,” “oligonucleotides,” “antisense,” and by review of bibliographical references list (in "snowball") of the selected studies.

Results: There is a wide variety of bibliographic evidence about Lp(a), its importance in the development of arteriosclerotic disease, and multiple pharmacological options; both approved and under development, using this molecule as a therapeutic target.

Conclusions:  Comprehending Lp(a) mechanisms provides new explanations about the atherosclerotic cardiovascular disease; antisense oligonucleotides are currently in pharmacological development, expected to be a promising therapy to modify its concentration. However, it is necessary to await the outcomes of phase III in trials to confirm preliminary results.
PDF (Español (España))
HTML (Español (España))


WHO. Cardiovascular diseases. 2023. [Citado el 5 de abril de 2023]. Disponible en:

Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgözo?lu L, Lewis EF. Atherosclerosis. Nat Rev Dis Primers. 2019 aug. 16;5(1):56.

Augusto G, Victor A, Curt D, Francesco C, Hans S, Erling F, et. al. Non-coronary atherosclerosis. European Heart Journal. 2014 may. 1; 35(17):1112–1119.

Katharina L, Clemens von S, Amy LM, Nicolai W, Uwe N, Benjamin L, et. al. Lifestyle factors and high-risk atherosclerosis: pathways and mechanisms beyond traditional risk factors, European Journal of Preventive Cardiology. 2020 mar. 1; 27(4):394–406.

Libby P. The changing landscape of atherosclerosis. Nature. 2021 apr.;592(7855):524-533.

Kostner GM. Lp(a) Biochemistry, Composition, and Structure. In: Kostner K, Kostner GM, Toth PP, (eds). Lipoprotein(a). Humana, Cham: Contemporary Cardiology; 2023. p. 39-54.

Kaiser Y, Daghem M, Tzolos E, Meah MN, Doris MK, Moss AJ, et. al. Association of Lipoprotein(a) With Atherosclerotic Plaque Progression. J Am Coll Cardiol. 2022 jan. 25;79(3):223-233.

Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et. al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022 jan.;42(1): e48-e60.

Saeed A, Kinoush S, Virani SS. Lipoprotein (a): Recent Updates on a Unique Lipoprotein. Curr Atheroscler Rep. 2021 jun. 19;23(8):41.

Duarte F, Giugliano RP. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022 jul. 1;7(7):760-769.

Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J. 2019 mar.-apr.;71(2):99-112.

Shah NP, Pajidipati NJ, McGarrah RW, Navar AM, Vemulapalli S, Blazing MA, et. al. Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. Am J Cardiol. 2020 jul. 1;126:94-102.

Kamstrup PR. Lipoprotein(a) and Cardiovascular Disease. Clin Chem. 2021 jan.;67(1):154-166.

Kronenberg F. Lipoprotein(a). In: von Eckardstein A, Binder CJ (eds). Prevention and Treatment of Atherosclerosis. Springer, Cham: Handbook of Experimental Pharmacology; 2021. vol 270. p. 201-232.

Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et. al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2022 sep.;16(5):e77-e95.

Mehta A, Vasquez N, Ayers CR, Patel J, Hooda A, Khera A, et. al. Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk. J Am Coll Cardiol. 2022 mar. 1;79(8):757-768.

Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017 feb. 14;69(6):692-711.

Markus MRP, Ittermann T, Schipf S, Bah M, Nauck M, Völzke H, et. al. Association of sex-specific differences in lipoprotein(a) concentrations with cardiovascular mortality in individuals with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021 aug. 18;20:168.

Simony SB, Mortensen MB, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG. Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study. Atherosclerosis. 2022 Aug.;355:76-82.

Forbang NI, Criqui MH, Allison MA, Ix JH, Steffen BT, Cushman M, et. al. Sex and ethnic differences in the associations between lipoprotein(a) and peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis. J Vasc Surg. 2016 feb.;63(2):453-458.

Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016 apr.;57(4):526-37.

Cegla J, Neely RDG, France M, Ferns G, Byrne CD, Halcox J, et. al. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis. 2019 dec.;291:62-70.

Ward NC, Watts GF, Bishop W, Colquhoun D, Hamilton-Craig C, Hare DL, et. al. Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations. Heart Lung Circ. 2023 mar.;32(3):287-296.

Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et. al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 oct. 14;43(39):3925-3946.

Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et. al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021 aug.;37(8):1129-1150.

Newman CB, Blaha MJ, Boord JB, Cariou B, Chait A, Fein HG, et. al. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endo & Met. 2020 dec. 19;105(12):3613–3682.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et. al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart J. 2020 jan. 1;41(1):111-118.

Grundy S, Stone N, Bailey A, Beam C, Birtcher KK, Blumenthal RS, et. al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 jun. 25;73(24):e285–e350.

Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019 jan. 17;124(2):315-327.

Gimbrone MA Jr, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016 feb. 19;118(4):620-636.

Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han X, et. al. Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules. 2018 aug. 23;8(3):80.

Khosravi M, Poursaleh A, Ghasempour G, Farhad S, Najafi M. The effects of oxidative stress on the development of atherosclerosis. Biological Chemistry. 2019;400(6):711-732.

Ruparelia N, Choudhury R. Inflammation and atherosclerosis: what is on the horizon? Heart. 2020 jan.;106(1):80-85.

Schaftenaar F, Frodermann V, Kuiper J, Lutgens E. Atherosclerosis: the interplay between lipids and immune cells. Curr Opin Lipidol. 2016 jun.;27(3):209-215.

Torres N, Guevara-Cruz M, Velázquez-Villegas LA, Tovar AR. Nutrition and Atherosclerosis. Arch Med Res. 2015 jul.;46(5):408-426.

Bennett MR, Sinha S, Owens GK. Vascular Smooth Muscle Cells in Atherosclerosis. Circ Res. 2016 feb 19;118(4):692-702.

Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y, et. al. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis. Atherosclerosis. 2017 apr.;259:75-82.

Badimon L, Peña E, Arderiu G, Padró T, Slevin M, Vilahur G, et. al. C-Reactive Protein in Atherothrombosis and Angiogenesis. Front Immunol. 2018 mar. 2;9:430.

Xu S, Pelisek J, Jin ZG. Atherosclerosis Is an Epigenetic Disease. Trends Endocrinol Metab. 2018 may. 9;29(11):739-742.

Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, et. al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol. 2018 jul. 1;3(7):619-627.

Leibundgut G, Scipione C, Yin H, Schneider M, Boffa MB, Green S, et. al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res. 2013 oct.;54(10):2815-2830.

Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, et. al. Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules. 2023 jan. 18;28(3):969.

Anglés-Cano E, Rojas G. Apolipoprotein(a): Structure-Function Relationship at the Lysine-Binding Site and Plasminogen Activator Cleavage Site. 2002;383(1):93-99.

Boffa MB. Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis. Atherosclerosis. 2022 may.;349:72-81.

Tabas I, Li Y, Brocia RW, Xu SW, Swenson TL, Williams KJ. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation. J Biol Chem. 1993 sep. 25;268(27):20419-20432.

McLean, J, Tomlinson J, Kuang WJ, Eaton DL, Chen EY, Fless GM. et. al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132–137.

Ugovšek S, Šebeštjen M. Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation. Biomolecules. 2021 dec. 24;12(1):26.

Labudovic D, Kostovska I, Tosheska K, Cekovska S, Brezovska J, Topuzovska S. Lipoprotein(a) - Link between Atherogenesis and Thrombosis. Prague Med Rep. 2019;120(2-3):39-51.

Wiesner P, Tafelmeier M, Chittka D, Choi SH, Zhang L, Byun YS, et. al. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res. 2013 jul.;54(7):1877-1883.

Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et. al.. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022 mar. 5;29(5):779-792.

Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et. al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. The Lancet. 2018 oct. 13;392(10155):1311-1320.

Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020 jun. 21;41(24):2275-2284.

Awad K, Mikhailidis DP, Katsiki N, Munter P, Banach M. Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Drugs. 2018;78:453–462.

Sahebkar A, Simental-Mendía LE, Pirro M, Banach M, Watts GF, Sitori C, et. al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018 dec.;8:17887.

Farmakis I, Doundoulakis I, Pagiantza A, Zafeiropoulos S, Antza C, Karvounis H, et. al. Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis. J Cardiovasc Pharmacol. 2021 mar.;77(3):397-407.

Ge X, Zhu T, Zeng H, Yu X, Li J, Xie S, et. al.. A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia. Biomed Res Int. 2021 oct. 31;2021:8032978.

O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et. al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483-1492.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et. al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 may. 4;376:1713-1722.

Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et. al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol. 2020 jan. 21;75(2):133-144.

Julius U, Fischer S. Nicotinic acid as a lipid-modifying drug--a review. Atheroscler Suppl. 2013 jan.;14(1):7-13.

Sahebkar A, Reiner Ž, Simental-Mendía LE, Ferretti G, Cicero AF. Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism. 2016 nov.;65(11):1664-1678.

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et. al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016 oct. 14;37(39):2999-3058.

Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart. 2016 jan. 14;102:198-203.

Zhou J, Zhang Q, Wang Y, Gao P, Chen D. The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis. Postgrad Med. 2018;130(1):129-136.

HPS3/TIMI55–REVEAL Collaborative Group. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017 sep. 28;377:1217-1227.

HPS3/TIMI55-REVEAL Collaborative Group. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J. 2022 apr. 7;43(14):1416-1424.

Nugent AK, Gray JV, Gorby LK, Moriarty PM. Lipoprotein apheresis: First FDA indicated treatment for elevated lipoprotein(a). J Clin Cardiol. 2020;1(1):16–21.

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et. al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014 sep.;8(5):473-488.

Schettler V, Neumann CL, Hulpke-Wette M, Hagenah GC, Schulz EG, Wieland E, et. al. Current view: indications for extracorporeal lipid apheresis treatment. Clin Res Cardiol Suppl. 2012 jun.;7(Suppl 1):15-9.

Lloyd-Jones D, Morris P, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et. al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Comitte. J Am Coll Cardiol. 2022 oct. 4;80(14):1366–1418.

Nurmohamed NS, Kraaijenhof JM, Stroes ESG. Lp(a): a New Pathway to Target? Curr Atheroscler Rep. 2022 nov.;24:831-838.

Schettler VJJ, Peter C, Zimmermann T, Julius U, Roeseler E, Schlieper G, et. al. The German Lipoprotein Apheresis Registry-Summary of the ninth annual report. Ther Apher Dial. 2022 dec.5;26 (Suppl 1):81-88.

Borrelli MJ, Youssef A, Boffa MB, Koschinsky ML. New Frontiers in Lp(a)-Targeted Therapies. Trends Pharmacol Sci. 2019 mar.;40(3):212-225.

Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et. al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 apr. 16;382:1507-1519.

Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et. al.. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 apr. 16;382:1520-1530.

U.S. Food & Drug Administration. FDA approves add-on therapy to lower cholesterol among certain high-risk adults. U.S. Food and Drug Administration. FDA [Citado el 6 de abril de 2023]. Disponible en:

O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, et. al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022 nov.

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial. [Citado el de 6 abril de 2023]. Disponible en:

Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et. al. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA. 2022 apr. 3;327(17):1679-1687.

Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events. [Citado el de 6 abril de 2023]. Disponible en:

Lacaze P, Bakshi A, Riaz M, Polekhina G, Owen A, Bhatia HS, et. al. Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes. J Am Coll Cardiol. 2022 oct 4;80(14):1287-1298.

Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. JAMA. 2019 jan.;321(3):277–287.

Abdelaziz HK, Saad M, Pothineni NVK, Megaly M, Potluri R, Saleh M, et. al. Aspirin for Primary Prevention of Cardiovascular Events. J Am Coll Cardiol. 2019 jun. 18;73(23):2915-2929.

Nudy M, Cooper J, Ghahramani M, Ruzieh M, Mandrola J, Foy AJ. Aspirin for Primary Atherosclerotic Cardiovascular Disease Prevention as Baseline Risk Increases: A Meta-Regression Analysis. Am J Med. 2020 sep.;133(9):1056-1064.

Masson G, Lobo M, Masson W, Molinero G. Aspirina en la prevención primaria. Metaanálisis estratificado por riesgo vascular basal. Arch Cardiol Mex. 2020;90(3):293-299.

Wang M, Yu H, Li Z, Gong D, Liu X. Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis. Am J Cardiovasc Drugs. 2022;22:657–675

Christiansen M, Grove EL, Hvas AM. Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than Benefit-A Systematic Review and Meta-Analysis. Semin Thromb Hemost. 2019;45(5):478-489.

Gheibi-Hayat SM, Jamialahmadi K. Antisense Oligonucleotide (AS-ODN) Technology: Principle, Mechanism and Challenges. Biotechnol Appl Biochem. 2021 oct.;68(5):1086-1094.

Ibrahim S, Stroes ESG. Therapy of Elevated Lipoprotein(a). In: Kostner K, Kostner GM, Toth PP, (eds). Lipoprotein(a). Humana, Cham: Contemporary Cardiology. Humana, Cham. 2023. p.347-357.

Tsimikas S. Antisense Oligonucleotide Therapy to Treat Elevated Lipoprotein(a). In: Kostner K, Kostner GM, Toth PP, (eds). Lipoprotein(a). Humana, Cham: Contemporary Cardiology. 2023. p.359-375.

Blom DJ, Marais AD, Moodley R, van der Merwe N, van Tonder A, Raal FJ. RNA-based therapy in the management of lipid disorders: a review. Lipids Health Dis. 2022 apr. 23;21(1):41.

Melita H, Manolis AA, Manolis TA, Manolis AS. Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk. J Cardiovasc Pharmacol. 2022 jan.;79(1):e18-e35.

Panta R, Dahal K, Kunwar S. Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials. J Clin Lipidol. 2015 mar.;9(2):217-225.

Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, et. al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015 oct. 10;386(10002):1472-1483.

Hardy J, Niman S, Goldfaden RF, Ashchi M, Bisharat M, Huston J, et. al. A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent. Am J Cardiovasc Drugs. 2022 jan.;22:47-54.

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et. al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. The Lancet. 2016 nov. 5;388(10057):2239-2253.

Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et. al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020 jan. 16;382:244-255.

Tsimikas S, Moriarty PM, Stroes ES. Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. J Am Coll Cardiol. 2021 mar. 30;77(12):1576-1589.

Assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with CVD.[Citado el de 6 abril de 2023]. Disponible en:

Hao Q, Aertgeerts B, Guyatt G, Bekkering GE, Vandvik PO, Khan SU, et. al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ. 2022 may. 4;377:e069066.

Gallego-Colon E, Daum A, Yosefy C. Statins and PCSK9 inhibitors: A new lipid-lowering therapy. Eur J Pharmacol. 2020 jul. 5;878:173114.

Cai T, Abel L, Langford O, Monaghan G, Aronson JK, Stevens RJ, et. al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021 jul. 15;374:n1537.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2023 Revista Colombiana de Endocrinología, Diabetes & Metabolismo




Download data is not yet available.